Sugi Predict

Sugi Predict / Compounds / SCHEMBL186090

SCHEMBL186090

SCHEMBL186090

CCCC[C@H](N)C(=O)OC

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.59
▸ CA2 P00918 3/20 0.59
▸ DPP7 Q9UHL4 8/20 0.53
▸ SLC15A1 P46059 1/20 0.53
▸ ZDHHC7 Q9NXF8 1/20 0.50
▸ DPP9 Q86TI2 6/20 0.49
▸ DPP8 Q6V1X1 5/20 0.49
▸ DPP4 P27487 5/20 0.49
▸ METAP1 P53582 1/20 0.47
▸ SLC1A3 P43003 1/20 0.46
▸ SLC1A2 P43004 1/20 0.46
▸ SLC1A1 P43005 1/20 0.46
▸ ERAP2 Q6P179 2/20 0.42
▸ LNPEP Q9UIQ6 2/20 0.42
▸ GNAI3 P08754 1/20 0.42
▸ GNAO1 P09471 1/20 0.42
▸ GNAI1 P63096 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL628944 1.00 CA1 (0.59) CA1CA2DPP7SLC15A1ZDHHC7
SCHEMBL3649449 1.00 CA1 (0.59) CA1CA2DPP7SLC15A1ZDHHC7
Hydrochloric Acid SCHEMBL5192659 0.98 CA1 (0.57) CA1CA2DPP7SLC15A1ZDHHC7
Hydrochloric Acid SCHEMBL186088 0.98 CA1 (0.57) CA1CA2DPP7SLC15A1ZDHHC7
Hydrochloric Acid SCHEMBL186089 0.98 CA1 (0.57) CA1CA2DPP7SLC15A1ZDHHC7
SCHEMBL13295626 0.94 ZDHHC7 (0.58) CA1CA2DPP7SLC15A1ZDHHC7
SCHEMBL12041935 0.94 ZDHHC7 (0.58) CA1CA2DPP7SLC15A1ZDHHC7
SCHEMBL5192545 0.94 ZDHHC7 (0.58) CA1CA2DPP7SLC15A1ZDHHC7
SCHEMBL5477583 0.92 ZDHHC7 (0.61) CA1CA2DPP7SLC15A1ZDHHC7
SCHEMBL22551133 0.92 ZDHHC7 (0.61) CA1CA2DPP7SLC15A1ZDHHC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12358951-B2 Cyclic peptide antibiotics GENENTECH, INC. (US) 2025-07-15 — — US disclosed
US-20250115571-A1 OXOPIPERAZINE DERIVATIVES Inthera Bioscience AG (CH) 2025-04-10 — — US disclosed
EP-4501942-A1 PEPTIDOMIMETICS WITH ANTIVIRAL ACTIVITY Consejo Superior De Investigaciones Científicas (CSIC) (ES) 2025-02-05 — — EP disclosed
US-20240398757-A1 INHIBITORS FOR CORONAVIRUSES COCRYSTAL PHARMA, INC. 2024-12-05 — — US disclosed
US-12012393-B2 Oxopiperazine derivatives Inthera Bioscience AG (CH) 2024-06-18 — — US disclosed
EP-4380920-A1 INHIBITORS FOR CORONAVIRUSES Cocrystal Pharma, Inc. (US) 2024-06-12 — — EP disclosed
CN-118103351-A Coronavirus inhibitors 共晶制药公司 2024-05-28 — — CN disclosed
CN-110770209-B Novel 5-hydroxypyridine compounds useful as P2X1 and P2X3 receptor antagonists and pharmaceutical compositions containing the same 光州科学技术院 2023-06-30 — — CN disclosed
US-20230190950-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS CIDARA THERAPEUTICS, INC. 2023-06-22 — — US disclosed
US-20230190950-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS CIDARA THERAPEUTICS, INC. 2023-06-22 — — US disclosed
US-4792555-A DESENSITIZERS; ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1988-12-20 — — US disclosed
WO-1988006885-A1 PHOSPHOLIPASE A2 INHIBITORS AMERICAN HOME PRODUCTS CORPORATION (US) 1988-09-22 — — WO disclosed
WO-1988006600-A1 SUBSTITUTED ALKYLAMIDES OF TEICOPLANIN COMPOUNDS GRUPPO LEPETIT S.P.A. (IT) 1988-09-07 — — WO disclosed
US-4766110-A INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS RYAN JAMES W (US) 1988-08-23 — — US disclosed
US-4645678-A FOR FOOD OR PHARMACEUTICAL PRODUCTS UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) 1987-02-24 — — US disclosed
EP-0209855-A2 Amino acid derivatives useful for deactivating enzymes Board of Trustees of Wichita State University (US) 1987-01-28 — — EP disclosed
US-4595674-A Pharmaceuticals BAYER AKTIENGESELLSCHAFT (DE) 1986-06-17 — — US disclosed
EP-0107597-B1 CHEMICAL COMPOUNDS AND THEIR USE AS SWEETENING AGENTS UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) 1986-02-26 — — EP disclosed
EP-0107597-A1 Chemical compounds and their use as sweetening agents UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) 1984-05-02 — — EP disclosed
US-4425269-A Metabolically protected analogs of neurotensin MERCK & CO., INC. (US) 1984-01-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240398757-A1 INHIBITORS FOR CORONAVIRUSES ACE, ACE2, SARS1 CA1 1862/4885CA2 1835/4885DPP7 665/4885
US-20250115571-A1 OXOPIPERAZINE DERIVATIVES CYP3A5, AQP1, AVPR2 CA1 2821/4885CA2 1597/4885DPP7 710/4885
US-12358951-B2 Cyclic peptide antibiotics NPPA, LNPEP, CLPP CA1 4539/4885CA2 3912/4885DPP7 43/4885
US-20230190950-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS FCGR3B, FCGR1A, FCGR2A CA1 1603/4885CA2 1661/4885DPP7 1358/4885
US-12012393-B2 Oxopiperazine derivatives CYP3A5, AQP1, AVPR2 CA1 2821/4885CA2 1597/4885DPP7 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.